The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir.
Isidori
Alessandro
A
Visani
Giuseppe
G
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000276:immunology / Q000821:virology*; D015774:Ganciclovir / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D015774:Ganciclovir